Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.
Researchers investigated the association between specimen length and number of sections evaluated and the diagnostic yield of temporal artery biopsy for giant cell arteritis.
Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.
ChemoCentryx, Inc has submitted a NDA to the FDA for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis relapse in GPA or MPA.
Researchers evaluated the efficacy and safety of avacopan for the treatment of ANCA-associated vasculitis.
Study leads Shilpa Venkatachalam, PhD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.
Between one-fifth and one-third of patients with rheumatoid arthritis, connective tissue disease, and vasculitis have ocular complications.
Investigators characterized the effects and markers of response of omalizumab in normocomplementemic urticarial vasculitis.
Researchers in the PEXIVAS trial evaluated and challenged the effect of plasma exchange and glucocorticoid use in ANCA-associated vasculitis.